Abraxis BioScience acquired a sterile injectable Phoenix-based manufacturing plant from Watson Pharmaceuticals. The facility, which has the ability to produce lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for both Watson and other third parties.
The facility is approximately 200,000 sq. ft. and includes manufacturing as well as chemistry and microbiology laboratories. Abraxis officials say that this plant, along with its manufacturing site located in Melrose Park, IL, will produce the company’s current and future products. This is expected to take place after completion of the planned separation of its product business—Abraxis Oncology and Abraxis Research (the new Abraxis BioScience)—from its hospital-based product business, Abraxis Pharmaceutical Products.
Also, Abraxis will serve as a contract manufacturer for certain injectable products currently produced in this site for a specified period of time.